Skip to main content
EFSA Journal logoLink to EFSA Journal
. 2011 Apr 8;9(4):2083. doi: 10.2903/j.efsa.2011.2083

Scientific Opinion on the substantiation of health claims related to: anthocyanidins and proanthocyanidins (ID 1787, 1788, 1789, 1790, 1791); sodium alginate and ulva (ID 1873); vitamins, minerals, trace elements and standardised ginseng G115 extract (ID 8, 1673, 1674); vitamins, minerals, lysine and/or arginine and/or taurine (ID 6, 1676, 1677); plant‐based preparation for use in beverages (ID 4210, 4211); Carica papaya L. (ID 2007); “fish protein” (ID 651); acidic water‐based, non‐alcoholic flavoured beverages containing calcium in the range of 0.3 to 0.8 mol per mol of acid with a pH not lower than 3.7 (ID 1170); royal jelly (ID 1225, 1226, 1227, 1228, 1230, 1231, 1326, 1328, 1329, 1982, 4696, 4697); foods low in cholesterol (ID 624); and foods low in trans‐fatty acids (ID 672, 4333) pursuant to Article 13(1) of Regulation (EC) No 1924/2006

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
PMCID: PMC13129690  PMID: 42078765

The content is available as a PDF (483.8 KB).

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) ; Scientific Opinion on the substantiation of health claims related to: anthocyanidins and proanthocyanidins (ID 1787, 1788, 1789, 1790, 1791); sodium alginate and ulva (ID 1873); vitamins, minerals, trace elements and standardised ginseng G115 extract (ID 8, 1673, 1674); vitamins, minerals, lysine and/or arginine and/or taurine (ID 6, 1676, 1677); plant‐based preparation for use in beverages (ID 4210, 4211); Carica papaya L. (ID 2007); “fish protein” (ID 651); acidic water‐based, non‐alcoholic flavoured beverages containing calcium in the range of 0.3 to 0.8 mol per mol of acid with a pH not lower than 3.7 (ID 1170); royal jelly (ID 1225, 1226, 1227, 1228, 1230, 1231, 1326, 1328, 1329, 1982, 4696, 4697); foods low in cholesterol (ID 624); and foods low in trans‐fatty acids (ID 672, 4333) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA Journal 2011;9(4):2083. [34 pp.]. doi: 10.2903/j.efsa.2011.2083.

Panel members: Carlo Agostoni, Jean‐Louis Bresson, Susan Fairweather‐Tait, Albert Flynn, Ines Golly, Hannu Korhonen, Pagona Lagiou, Martinus Løvik, Rosangela Marchelli, Ambroise Martin, Bevan Moseley, Monika Neuhäuser‐Berthold, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Stephan Strobel, Inge Tetens, Daniel Tomé, Hendrik van Loveren and Hans Verhagen.

Correspondence: nda@efsa.europa.eu

Acknowledgement: The Panel wishes to thank for the preparatory work on this scientific opinion: The members of the Working Group on Claims: Carlo Agostoni, Jean‐Louis Bresson, Susan Fairweather‐Tait, Albert Flynn, Ines Golly, Marina Heinonen, Hannu Korhonen, Martinus Løvik, Ambroise Martin, Hildegard Przyrembel, Seppo Salminen, Yolanda Sanz, Sean (J.J.) Strain, Inge Tetens, Hendrik van Loveren and Hans Verhagen. The members of the Claims Sub‐Working Group on Gut/Immune: Jean‐Louis Bresson, Maria Carmen Collado, Miguel Gueimonde, Daisy Jonkers, Martinus Løvik, Bevan Moseley, Maria Saarela, Seppo Salminen, Yolanda Sanz, Stephan Strobel, Daniel Tomé and Hendrik van Loveren. The members of the Claims Sub‐Working Group on Cardiovascular Health/Oxidative Stress: Antti Aro, Marianne Geleijnse, Marina Heinonen, Ambroise Martin, Wilhelm Stahl and Henk van den Berg.

Adoption date: 17 February 2011

Published date: 8 April 2011

Question number: EFSA‐Q‐2008‐1411, EFSA‐Q‐2008‐1438, EFSA‐Q‐2008‐1459, EFSA‐Q‐2008‐1909, EFSA‐Q‐2008‐1963, EFSA‐Q‐2008‐1964, EFSA‐Q‐2008‐1965, EFSA‐Q‐2008‐1966, EFSA‐Q‐2008‐1968, EFSA‐Q‐2008‐1969, EFSA‐Q‐2008‐2063, EFSA‐Q‐2008‐2065, EFSA‐Q‐2008‐2066, EFSA‐Q‐2008‐2409, EFSA‐Q‐2008‐2410, EFSA‐Q‐2008‐2412, EFSA‐Q‐2008‐2413, EFSA‐Q‐2008‐2520, EFSA‐Q‐2008‐2521, EFSA‐Q‐2008‐2522, EFSA‐Q‐2008‐2523, EFSA‐Q‐2008‐2524, EFSA‐Q‐2008‐2606, EFSA‐Q‐2008‐2715, EFSA‐Q‐2008‐2740, EFSA‐Q‐2008‐4920, EFSA‐Q‐2008‐4921, EFSA‐Q‐2008‐793, EFSA‐Q‐2008‐795, EFSA‐Q‐2010‐00286, EFSA‐Q‐2010‐00649, EFSA‐Q‐2010‐00650

On request from: European Commission

References

  1. Bincoletto C, Eberlin S, Figueiredo CA, Luengo MB and Queiroz ML, 2005. Effects produced by Royal Jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge. International Immunopharmacology, 5, 679–688. [DOI] [PubMed] [Google Scholar]
  2. Fontana R, Mendes MA, de Souza BM, Konno K, Cesar LM, Malaspina O and Palma MS, 2004. Jelleines: a family of antimicrobial peptides from the Royal Jelly of honeybees (Apis mellifera). Peptides, 25, 919–928. [DOI] [PubMed] [Google Scholar]
  3. Marotta F, Weksler M, Naito Y, Yoshida C, Yoshioka M and Marandola P, 2006. Nutraceutical supplementation: effect of a fermented papaya preparation on redox status and DNA damage in healthy elderly individuals and relationship with GSTM1 genotype: a randomized, placebo‐controlled, cross‐over study. Annals of the New York Academy of Sciences, 1067, 400–407. [DOI] [PubMed] [Google Scholar]
  4. Sver L, Orsolic N, Tadic Z, Njari B, Valpotic I and Basic I, 1996. A royal jelly as a new potential immunomodulator in rats and mice. Comparative Immunology, Microbiology and Infectious Diseases, 19, 31–38. [DOI] [PubMed] [Google Scholar]
  5. Torun B, 2005. Protein: Quality and Sources. In: Encyclopedia of Human Nutrition. Eds Caballero B, Allen L, Prentice A. Elsevier, Oxford. [Google Scholar]

Articles from EFSA Journal are provided here courtesy of Wiley

RESOURCES